NO803254L - Opploesningsmiddelblanding og fremgangsmaate for fremstilling av parenteralt administrerbare injeksjonsopploesninger - Google Patents
Opploesningsmiddelblanding og fremgangsmaate for fremstilling av parenteralt administrerbare injeksjonsopploesningerInfo
- Publication number
- NO803254L NO803254L NO803254A NO803254A NO803254L NO 803254 L NO803254 L NO 803254L NO 803254 A NO803254 A NO 803254A NO 803254 A NO803254 A NO 803254A NO 803254 L NO803254 L NO 803254L
- Authority
- NO
- Norway
- Prior art keywords
- group
- general formula
- solvent mixture
- solution
- value
- Prior art date
Links
- 239000000243 solution Substances 0.000 title claims description 51
- 238000002347 injection Methods 0.000 title claims description 29
- 239000007924 injection Substances 0.000 title claims description 29
- 239000011877 solvent mixture Substances 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000002253 acid Substances 0.000 claims description 20
- HONLKDDLTAZVQV-UHFFFAOYSA-N eburnamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)N5C2=C1 HONLKDDLTAZVQV-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000004494 ethyl ester group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- HONLKDDLTAZVQV-UHOSZYNNSA-N vincanol Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](O)N5C2=C1 HONLKDDLTAZVQV-UHOSZYNNSA-N 0.000 claims description 11
- 229950002496 vincanol Drugs 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- -1 aliphatic alcohols Chemical class 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 229940035674 anesthetics Drugs 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims 2
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002726 vincamine Drugs 0.000 claims 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000008223 sterile water Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- VKTOXAGUZWAECL-OALUTQOASA-N eburnamenine Natural products C1=CC=C2C(CCN3CCC4)=C5[C@H]3[C@]4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-OALUTQOASA-N 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- VKTOXAGUZWAECL-UHFFFAOYSA-N trans-eburnamenine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-UHFFFAOYSA-N 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- OZDNDGXASTWERN-CTNGQTDRSA-N Apovincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-CTNGQTDRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229950006936 apovincamine Drugs 0.000 description 1
- OZDNDGXASTWERN-UHFFFAOYSA-N apovincamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VKTOXAGUZWAECL-RBUKOAKNSA-N eburnamenine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@H]3[C@@]4(CC)C=CN5C2=C1 VKTOXAGUZWAECL-RBUKOAKNSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU79RI733A HU181940B (en) | 1979-11-02 | 1979-11-02 | Process for producing solutions of vincane derivatives for parentheral application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO803254L true NO803254L (no) | 1981-05-04 |
Family
ID=11001115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803254A NO803254L (no) | 1979-11-02 | 1980-10-31 | Opploesningsmiddelblanding og fremgangsmaate for fremstilling av parenteralt administrerbare injeksjonsopploesninger |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4344950A (de) |
| JP (1) | JPS56123911A (de) |
| AR (1) | AR223735A1 (de) |
| AT (1) | AT377914B (de) |
| AU (1) | AU533715B2 (de) |
| BE (1) | BE885987A (de) |
| CA (1) | CA1159367A (de) |
| CH (1) | CH645019A5 (de) |
| CS (1) | CS226417B2 (de) |
| DD (1) | DD153760A5 (de) |
| DE (1) | DE3041368A1 (de) |
| DK (1) | DK464680A (de) |
| FI (1) | FI803401L (de) |
| FR (1) | FR2468373A1 (de) |
| GB (1) | GB2062464B (de) |
| HU (1) | HU181940B (de) |
| IL (1) | IL61310A (de) |
| IT (1) | IT1209367B (de) |
| NL (1) | NL8005980A (de) |
| NO (1) | NO803254L (de) |
| PH (1) | PH17037A (de) |
| SE (1) | SE8007569L (de) |
| YU (1) | YU278880A (de) |
| ZA (1) | ZA806468B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1170152B (it) * | 1982-07-19 | 1987-06-03 | Lilly Co Eli | Miglioramenti a o riguardanti formulazioni di vinca-alcaloidi |
| US4619935A (en) * | 1983-03-17 | 1986-10-28 | Eli Lilly And Company | Stable oncolytic formulations |
| US5360593A (en) * | 1987-12-29 | 1994-11-01 | Alcon Laboratories, Inc. | Heat sterilization of labile antibiotics |
| CN101721361B (zh) * | 2009-12-08 | 2013-06-26 | 李荣立 | 长春胺注射剂及其制备工艺 |
| CN112649522B (zh) * | 2020-11-30 | 2022-02-22 | 海南葫芦娃药业集团股份有限公司 | 一种注射液中有关物质长春胺酸与阿朴长春胺酸的检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005754A (en) * | 1957-08-16 | 1961-10-24 | Bristol Myers Co | Tetracycline formulations |
| US3155586A (en) * | 1963-01-23 | 1964-11-03 | American Cyanamid Co | Stable liquid preparations of 6-demethyltetracyclines |
| US3159542A (en) * | 1962-12-31 | 1964-12-01 | American Cyanamid Co | Stable aqueous glycol solution of tetracycline aluminum calcium gluconate complex having a ph of about 7. 5 to 9 |
| GB1005342A (en) * | 1963-01-23 | 1965-09-22 | Olin Mathieson | Pharmaceutical preparations containing choline ester salts |
| FR2191891B1 (de) * | 1972-07-13 | 1975-08-08 | Roussel Uclaf | |
| FR2279394A2 (fr) * | 1973-12-13 | 1976-02-20 | Saunier Laboratoires | Medicament pour le traitement des insuffisances circulatoires cerebrales |
-
1979
- 1979-11-02 HU HU79RI733A patent/HU181940B/hu unknown
-
1980
- 1980-10-20 IL IL61310A patent/IL61310A/xx unknown
- 1980-10-21 ZA ZA00806468A patent/ZA806468B/xx unknown
- 1980-10-23 CS CS807199A patent/CS226417B2/cs unknown
- 1980-10-27 AT AT0527980A patent/AT377914B/de not_active IP Right Cessation
- 1980-10-28 SE SE8007569A patent/SE8007569L/ unknown
- 1980-10-28 US US06/201,509 patent/US4344950A/en not_active Expired - Lifetime
- 1980-10-30 FI FI803401A patent/FI803401L/fi not_active Application Discontinuation
- 1980-10-30 YU YU02788/80A patent/YU278880A/xx unknown
- 1980-10-31 DD DD80224849A patent/DD153760A5/de unknown
- 1980-10-31 GB GB8035112A patent/GB2062464B/en not_active Expired
- 1980-10-31 BE BE0/202670A patent/BE885987A/fr not_active IP Right Cessation
- 1980-10-31 NO NO803254A patent/NO803254L/no unknown
- 1980-10-31 AR AR283093A patent/AR223735A1/es active
- 1980-10-31 DK DK464680A patent/DK464680A/da not_active Application Discontinuation
- 1980-10-31 CA CA000363725A patent/CA1159367A/en not_active Expired
- 1980-10-31 FR FR8023347A patent/FR2468373A1/fr active Granted
- 1980-10-31 AU AU64004/80A patent/AU533715B2/en not_active Ceased
- 1980-10-31 IT IT8025683A patent/IT1209367B/it active
- 1980-10-31 JP JP15235880A patent/JPS56123911A/ja active Pending
- 1980-10-31 CH CH813580A patent/CH645019A5/de not_active IP Right Cessation
- 1980-10-31 NL NL8005980A patent/NL8005980A/nl not_active Application Discontinuation
- 1980-11-02 PH PH24934A patent/PH17037A/en unknown
- 1980-11-03 DE DE19803041368 patent/DE3041368A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU6400480A (en) | 1981-05-07 |
| IT8025683A0 (it) | 1980-10-31 |
| CA1159367A (en) | 1983-12-27 |
| IT1209367B (it) | 1989-07-16 |
| DK464680A (da) | 1981-05-03 |
| ZA806468B (en) | 1981-10-28 |
| AU533715B2 (en) | 1983-12-08 |
| JPS56123911A (en) | 1981-09-29 |
| BE885987A (fr) | 1981-02-16 |
| SE8007569L (sv) | 1981-05-03 |
| IL61310A0 (en) | 1980-12-31 |
| FR2468373A1 (fr) | 1981-05-08 |
| CH645019A5 (de) | 1984-09-14 |
| US4344950A (en) | 1982-08-17 |
| GB2062464A (en) | 1981-05-28 |
| FR2468373B1 (de) | 1984-12-28 |
| FI803401L (fi) | 1981-05-03 |
| YU278880A (en) | 1984-04-30 |
| PH17037A (en) | 1984-05-17 |
| CS226417B2 (en) | 1984-03-19 |
| IL61310A (en) | 1984-08-31 |
| ATA527980A (de) | 1984-10-15 |
| HU181940B (en) | 1983-11-28 |
| NL8005980A (nl) | 1981-06-01 |
| DD153760A5 (de) | 1982-02-03 |
| GB2062464B (en) | 1983-12-07 |
| AT377914B (de) | 1985-05-28 |
| DE3041368A1 (de) | 1981-05-14 |
| AR223735A1 (es) | 1981-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0193287B1 (de) | Etoposid-Präparate | |
| US6559154B2 (en) | Composition of sodium channel blocking compound | |
| Connell et al. | Testosterone production by rabbit testis slices | |
| Hensens et al. | Neocarzinostatin chromophore: presence of a highly strained ether ring and its reaction with mercaptan and sodium borohydride | |
| EP0143478A1 (de) | Stabile, wässerige, saure, zur Einspritzung geeignete Lösung von Cis-Platinum | |
| JP2007507422A (ja) | テトロドトキシンの安定な凍結乾燥医薬製剤 | |
| NO803254L (no) | Opploesningsmiddelblanding og fremgangsmaate for fremstilling av parenteralt administrerbare injeksjonsopploesninger | |
| US4673666A (en) | 2-amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine gluconate and pharmaceutical preparations containing it | |
| DD159289A1 (de) | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen | |
| DE112016001715T5 (de) | Stabile flüssige pharmazeutische Zusammensetzungen von Bortezomib | |
| Pramanik | Galanin stimulates acetylcholine release in the rat striatum | |
| AU2020323037A1 (en) | SGLTS/DPP4 inhibitor and application thereof | |
| KR960007861B1 (ko) | 항종양성 안트라사이클린 글리코사이드-함유 즉시-사용형 주사 용액 및 이의 제조방법 | |
| IE59086B1 (en) | Preparation and use of new solvates of beclomthasone 17,21-dipropionate | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| EP0775485A1 (de) | Neue Verarbreichungsform von Hydroxocobalamin und ihre Verwendung zur Behandlung der Cyanidvergiftungen | |
| FI59336C (fi) | Foerfarande foer framstaellning av en oevermaettad isosorbiddinitratloesning | |
| JPS61106584A (ja) | 金属錯体を含有する水性医薬組成物 | |
| CN114642677A (zh) | 一种稳定的含有苦丁皂苷类化合物的液体药物组合物 | |
| JPH03206040A (ja) | 注射用溶液及びその調製方法 | |
| JPH0366617A (ja) | 静脈内投与用フエニトインナトリウム製剤 | |
| KR20060002825A (ko) | 알기닌아미드류를 함유하는 의약 제제 | |
| JP2014214156A (ja) | モルフィナン誘導体の結晶、その製造方法、およびそれを用いた医薬組成物 | |
| JP2022500350A (ja) | 安定したアザシチジン含有医薬組成物の製造方法 | |
| CN110317265B (zh) | 比伐芦定晶型a及其制备方法 |